Rep. Nathaniel Moran of Texas says America’s political debate around China’s biotech industry is fundamentally missing the point on where the real threat lies.
Moran, a Republican member of the House Select Committee on China, argues the US has become too fixated on measuring outcomes rather than understanding the inputs driving China’s rise.
“The United States has been too focused on measuring the outcomes of strategic scenarios with China and not paid enough attention to the input,” Moran told Fierce in a recent interview.
The congressman pointed specifically to early-stage supply chain activity as the area where China is pulling ahead, with consequences that will compound over time.
“We talk about the growing trials that are happening in China,” Moran said, outlining his concern that policymakers are looking at the wrong metrics when assessing competitive risk.
“What we forget to focus on is that they are beating us on our ground game. They’re doing things at the beginning of the supply chain that lead to the dominance on the output side of who controls the ultimate number of drugs that are important to the United States and our constituents.”
Moran has spoken publicly on Capitol Hill about China’s “aggressive push to dominate pharmaceuticals and biotechnology,” warning that the knowledge base advantage could shift rapidly.
“The knowledge base is going to start shifting quickly to China,” Moran told Fierce, framing the issue as one with long-term consequences for American drug availability and national security.
The congressman views the entire biotech competition between the two nations as part of a broader geopolitical “chess game” that requires more strategic thinking from US policymakers.
His concerns extend beyond innovation and research dominance to include practical questions about medicine supply chains and domestic manufacturing incentives across the country.
Moran said the right questions to be asking include: “Who’s controlling the market? Do we have our active pharmaceutical ingredients? Are we incentivizing manufacturing here in the United States?”
The skyrocketing use of Chinese biopharma companies as sources of innovation and licensing deals for US drug developers has drawn alarm from a growing number of politicians in Washington.
Moran has set out his thoughts in writing as well as in congressional settings, pushing for greater scrutiny of how Chinese firms are positioning themselves at the foundation of global pharmaceutical development.
The debate around Chinese biotech firms has intensified in recent years as deal volumes between US companies and Chinese developers have risen sharply, raising questions about dependency and data security.